ELOX (Eloxx Pharmaceuticals) ROC (Joel Greenblatt) %: 0.00% (As of Dec. 2025)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $11.81
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals ROC (Joel Greenblatt) %?

Eloxx Pharmaceuticals ELOX -0.76% 17 ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,320 Biotechnology companies, Eloxx Pharmaceuticals ranks worse than 79.77% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Eloxx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Eloxx Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

ELOX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -31475.59   Med: -5916.67   Max: -1218.9
Current: -3015.85

During the past 13 years, Eloxx Pharmaceuticals's highest ROC (Joel Greenblatt) % was -1218.90%. The lowest was -31475.59%. And the median was -5916.67%.

ELOX's ROC (Joel Greenblatt) % is ranked worse than
79.77% of 1320 companies
in the Biotechnology industry
Industry Median: -294.23 vs ELOX: -3015.85

Eloxx Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Eloxx Pharmaceuticals  (NAS:ELOX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Eloxx Pharmaceuticals ROC (Joel Greenblatt) % Related Terms


Eloxx Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals ROC (Joel Greenblatt) % Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,916.67 -2,571.88 -2,746.63 -1,218.90 0.00

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,916.67 -2,571.88 -2,746.63 -1,218.90 0.00

ELOX vs ESLA, RNXT, ABVC: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's ROC (Joel Greenblatt) % falls into.


ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.359 + 0 + 0.147) - (7.349 + 13.347 + 0.094999999999999)
=-18.285

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.485) - (4.361 + 11.816 + 0)
=-15.692

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Eloxx Pharmaceuticals for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.946/( ( (0 + max(-18.285, 0)) + (0 + max(-15.692, 0)) )/ 1 )
=-4.946/( ( 0 + 0 )/ 1 )
=-4.946/0
= %

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Eloxx Pharmaceuticals (ELOX) has a ROC (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eloxx Pharmaceuticals and its competitors. According to the industry distribution chart, Eloxx Pharmaceuticals ranks #1053 out of 1320 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Eloxx Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Eloxx Pharmaceuticals' current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Eloxx Pharmaceuticals ranks #1053 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' ROC (Joel Greenblatt) % compare to ESLA and RNXT?
According to the Biotechnology industry distribution chart, Eloxx Pharmaceuticals ranks #1053 out of 1320 companies for ROC (Joel Greenblatt) %. This places Eloxx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.81
Price